droiaventures.com Open in urlscan Pro
185.86.18.116  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Investor portal


 * About Droia
 * Droia Labs
 * Portfolio
 * People
 * News
 * Careers
 * Contact

 * About Droia
 * Droia Labs
 * Portfolio
 * People
 * News
 * Careers
 * Contact
 * Investor portal


MAKING A DIFFERENCE

Droia invests globally in young drug development companies that use novel
science and innovative approaches to bring promising therapies to patients. We
are specialists, investing exclusively in therapeutics for oncology and genetic
disease.

Our focus and our in-house team of drug development experts and biotech
professionals allow us to accelerate our companies’ progress by actively
supporting them from company creation through clinical proof of concept. We are
hands-on investors and entrepreneurs, fully dedicated to making an impact and
saving patient lives.


BREAKTHROUGH FOCUS

For biotech companies, ultimate success is measured in effective patient
benefit. Promising therapies should have a material impact on patient prognosis,
measured as a function of the severity of the unmet medical need addressed and
the improvement in therapeutic benefits as compared to (expected) standard of
care.

We only invest in companies that are able, through their technology platforms or
scientific insights, to go after previously unsolvable clinical problems.
Companies should differentiate not only by way of innovation, but also in the
way this innovation translates to clinical breakthrough.


GETTING IT DONE

Droia actively scouts for the best science and the best teams. Whether investing
in an existing company or creating a new company, we actively participate in our
portfolio companies’ development. Our team has deep and specialized experience
in disease biology, translational science, clinical development and company
building.

We have built many companies from the ground up, supporting and complementing
founders and management teams. Our team members dedicate their time to helping
their companies, and will take on interim roles within companies to help them
get off the ground faster. Our whole organization is geared towards doing what
we do best: building great drug development companies.


PORTFOLIO




ACCENT THERAPEUTICS (LEXINGTON, MASSACHUSETTS) IS DEVELOPING SMALL MOLECULE
THERAPIES IN THE EMERGING FIELD OF EPITRANSCRIPTOMICS. — ACCENTTX.COM


ACTIO BIOSCIENCES (SAN DIEGO, US) IS DEVELOPING A PORTFOLIO OF DRUGS TO MODULATE
THE ACTIVITY OF PROTEINS RESPONSIBLE FOR RARE DISEASES WITH THE POTENTIAL TO
TRANSLATE THESE FINDINGS INTO COMMON DISEASES – ACTIOBIO.COM


AMBAGON THERAPEUTICS (EINDHOVEN, NL AND SAN FRANCISCO US) IS DEVELOPING
FIRST-IN-CLASS CANCER DRUGS THROUGH TARGETED STABILIZATION OF 14-3-3 PROTEIN
COMPLEXES – AMBAGONTX.COM


ARCUS BIOSCIENCES (HAYWARD, CALIFORNIA; NYSE:RCUS) DEVELOPS SMALL-MOLECULES AND
ANTIBODIES TO COMPOSE PROPRIETARY IMMUNE-ONCOLOGY COMBINATIONS. THE COMPANY
TARGETS TUMOR RELATED IMMUNE SUPPRESSION, ENHANCED APC FUNCTION AND IMMUNE CELL
EFFICACY. — ARCUSBIO.COM


AURA BIOSCIENCES (CAMBRIDGE, MASSACHUSETTS; NASDAQ: AURA) DEVELOPS TUMOR
TARGETED VIRAL-LIKE NANOPARTICLES WHICH CAN ENCAPSULATE A WIDE RANGE OF
PAYLOADS. AURA’S LEAD PRODUCT IS IN CLINICAL TRIALS AGAINST OCULAR MELANOMA. —
AURABIOSCIENCES.COM


CRISTAL THERAPEUTICS (MAASTRICHT, THE NETHERLANDS) DEVELOPS A POLYMERIC
NANOPARTICLE DRUG DELIVERY PLATFORM ENHANCING THE PK PROPERTIES OF
CHEMOTHERAPEUTIC OR NUCLEOTIDE PAYLOADS AND IMPROVING THEIR UPTAKE IN THE TUMOR
MICROENVIRONMENT. — CRISTALTHERAPEUTICS.COM


CYTEIR THERAPEUTICS (LEXINGTON, MASSACHUSETTS; NASDAQ:CYT) IS DEVELOPING THE
NEXT GENERATION OF SYNTHETIC LETHAL THERAPIES TO TREAT CANCER AND AUTOIMMUNE
DISEASE. — CYTEIR.COM


FRONTIER MEDICINES (SOUTH SAN FRANCISCO, CALIFORNIA) LEVERAGES CHEMOPROTEOMICS
AND MACHINE LEARNING TO ACCELERATE THE DEVELOPMENT OF MEDICINES THAT DRUG THE
“UNDRUGGABLE” PROTEIN TARGETS THAT DRIVE HUMAN DISEASE. — FRONTIERMEDS.COM


HIGHLIGHT THERAPEUTICS (MADRID, SPAIN) DEVELOPS NANOCOMPLEXES OF SYNTHETIC DSRNA
THAT TARGET PAMP RECEPTORS AND TLRS TO INDUCE POWERFUL IMMUNE RESPONSES.
BIONCOTECH IS CLINICALLY EVALUATING SEVERAL IMMUNE-ONCOLOGY COMBINATIONS WITH
ITS LEAD PRODUCT. — HIGHLIGHTTHERAPEUTICS.COM


HUMMINGBIRD BIOSCIENCE IS DEVELOPING HIGHLY DIFFERENTIATED BIOTHERAPEUTICS
AGAINST SPECIFIC TARGETS IN CANCER AND AUTOIMMUNE DISEASE THROUGH ITS UNIQUE
ANTIBODY DISCOVERY PLATFORM. — HUMMINGBIRDBIOSCIENCE.COM


MAHZI THERAPEUTICS’ (CALIFORNIA, UNITED STATES) RESEARCH AND DEVELOPMENT EFFORTS
ARE FOCUSED ON RARE GENETIC NEURODEVELOPMENTAL DISORDERS – MAHZI.COM


MONTIS BIOSCIENCES (LEUVEN, BELGIUM) DEVELOPS NOVEL IMMUNO-ONCOLOGY THERAPEUTICS
TARGETING THE INTERSECTION BETWEEN PERIVASCULAR MACROPHAGES AND TUMOR
VASCULATURE — MONTISBIOSCIENCES.COM


MUNA THERAPEUTICS (COPENHAGEN, DENMARK & LEUVEN, BELGIUM) PIONEERS THE
DEVELOPMENT OF CNS PENETRANT SMALL MOLECULES AIMED TO SLOW DOWN THE PROGRESSION
OF SEVERAL NEURODEGENERATIVE DISEASES (ALZHEIMER’S, PARKINSON’S, AMYOTROPHIC
LATERAL SCLEROSIS (ALS), FRONTOTEMPORAL DEMENTIA (FTD)). — MUNATHERAPEUTICS.COM


OCTIMET (BEERSE, BELGIUM) IS DEVELOPING A NEW GENERATION OF HIGHLY SELECTIVE MET
KINASE INHIBITORS WITH AUGMENTED THERAPEUTIC INDEX. THE LEAD COMPOUND WAS
LICENSED FROM J&J AND IS BEING CLINICALLY TESTED IN SPECIFIC MET MUTATED PATIENT
POPULATIONS. — OCTIMET.COM


PACT PHARMA (HAYWARD, CALIFORNIA) DEVELOPS NEOANTIGEN-SPECIFIC ADOPTIVE TCR
T-CELL THERAPIES. PACT’S PROPRIETARY NEOANTIGEN IDENTIFICATION TECHNOLOGY
ADVANCES THE FEASIBILITY, POTENCY AND AFFORDABILITY OF PERSONALIZED CELL THERAPY
FOR CANCER. — PACTPHARMA.COM


QURALIS (CAMBRIDGE, MASSACHUSETTS) DEVELOPS NEW THERAPIES AGAINST AMYOTROPHIC
LATERAL SCLEROSIS (ALS), THE MOST COMMON FORM OF ADULT MOTOR NEURON DISEASE. –
QURALIS.COM


TUSK THERAPEUTICS (STEVENAGE, UK – ACQUIRED BY ROCHE) IS DEVELOPING NOVEL IMMUNE
MODULATING ANTIBODIES BASED ON AN IN-DEPTH UNDERSTANDING OF THE INNATE AND
ADAPTIVE IMMUNE SYSTEM. — TUSKTHERAPEUTICS.COM


VICINITAS THERAPEUTICS (SAN FRANCISCO, US) IS DEVELOPING THE DEUBIQUITINASE
TARGETING CHIMERA (DUBTAC) PLATFORM TO THERAPEUTICALLY STABILIZE ABERRANTLY
DEGRADED PROTEINS IN GENETIC DISEASES AND CANCER. — VICINITASTX.COM


VICO THERAPEUTICS (LEIDEN, THE NETHERLANDS) WORKS ON RNA MODULATING THERAPIES
FOR RARE NEUROLOGICAL DISORDERS, DEVELOPING ANTISENSE OLIGONUCLEOTIDE AGAINST
SPINOCEREBELLAR ATAXIA, HUNTINGTON’S DISEASE AND RETT SYNDROME. – VICOTX.COM


VOLASTRA THERAPEUTICS (NY, USA) TARGETS CHROMOSOMAL INSTABILITY TO TACKLE
METASTASES AND THERAPEUTIC RESISTANCE. — VOLASTRATX.COM


PEOPLE



 * M.Sc. Engineering, University of Leuven
 * MBA, INSEAD
 * McKinsey & Company
 * Waterland Private Equity

* representing Wepaven BV

JANWILLEM NAESENS *

Managing Partner, Oncology & Droia Group


 * Pharm.D., University of Leuven
 * MBA, Vlerick Management School
 * Arthur D. Little
 * TiGenix
 * Prosensa
 * Tusk Therapeutics
 * Independent board member Erytech, Pharvaris

* representing Primix Bio Ventures BV

LUC DOCHEZ *

Managing Partner, Genetic Disease


 * M.Sc. Bio-Engineering, University of Leuven
 * Founder / former owner of Verelst real estate group
 * Seasoned investor in small and big biotech, venture capital
 * Founder of the Anti Cancer Fund and the Verelst Uterine Cancer Fund



LUC VERELST

Founder & Chairman


 * BA in Biology, University of Virginia
 * PhD in Genetics, University of Wisconsin-Madison
 * Novartis
 * Celgene (Bristol Myers Squibb)
 * Arch Venture Partners
 * Board member Acceleron Pharma, Sage Therapeutics, Carrick Therapeutics,
   Shattuck Labs and others



GEORGE GOLUMBESKI

Partner


 * Group leader at the Netherlands Cancer Institute
 * Head of the NKI Robotics and Screening Center
 * Expert in large scale functional genomics
 * Pioneer of pooled screening technology
 * Co-founder of Qameleon Therapeutics



RODERICK BEIJERSBERGEN

Investment Advisory Board


 * BA in Biochemistry, Catholic University in Chile
 * PhD in Cell Biology, UCSF
 * Medivation
 * Praxis Biotech
 * Merken Biotech



SEBASTIAN BERNALES

Venture Partner


SOPHIE BERNIER

Compliance Manager


 * Master of laws, University of Ghent and University of Auckland
 * LL.M, New York University
 * Freshfields Bruckhaus Deringer



HELEEN BOONEN

Legal Counsel


 * Master in pharmaceutical sciences, UGent
 * PhD Biochemistry, UGent
 * MBA, Vlerick School for management
 * Founder of VIB
 * Managing Director VIB 1995-2022
 * Non executive director of companies and research institutions



JO BURY

Investment Advisory Board


NATHALIE DE BLIECK

Reporting & Accounting Specialist


 * Master of applied economic sciences KULeuven
 * First laureate BIBF awards
 * Deloitte M&A
 * Finance director CRANIUM

* representing Consillis BV

SVEN COLLIN

Director of Finance and Accounting


 * PhD Biomedical Sciences, University of Leuven
 * Doctoral Research at Angiogenesis and Vascular Metabolism lab (VIB) and Woman
   & Child unit, Cystic Fibrosis lab (KU Leuven/UZ Leuven)
 * MSc Biochemistry-Biotechnology, University of Leuven
 * MSc Management, University of Leuven



MATHIAS DECLERCQ

Scientific Analyst


 * Master of laws, University of Leuven
 * M.Sc. law and finance, Oxford University and Saïd Business School
 * Cleary Gottlieb Steen & Hamilton
 * Freshfields Bruckhaus Deringer
 * Etex Group

* representing MARA Consulting BV

MATTHIAS DE WITTE *

Chief Financial Officer and General Counsel


 * MSc Cancer, University College London
 * PhD Biomedical Sciences, University of Leuven
 * Doctoral research in Angiogenesis and Vascular Metabolism lab, VIB
 * FWO PhD Fellowship
 * The UCL Cancer Institute Research Trust and Athena SWAN award for Excellence
   in Science 2014



PAULINE DE ZEEUW

Scientific Analyst


BUJANA DRAGJOSHI

Accountant


 * BS Biochemistry, Boston College
 * MBA, MIT Sloan
 * Novartis
 * Deloitte Consulting
 * Third Rock Ventures
 * Goldfinch Bio



THOMAS MARTZ

Entrepreneur In Residence


 * M. Sc. Biochemistry-Biotechnology, University Leuven
 * PhD Biomedical sciences-Angiogenesis Vascular Metabolism, VIB
 * Postdoctoral Fellow - Immuno-Oncology, VIB
 * Postdoctoral Fellow - Tumor metabolism, University Pennsylvania
 * B.A.E.F. Postdoctoral Fellowship



RINDERT MISSIAEN

Scientific Analyst


 * PhD in Biomedical Sciences, KULeuven
 * Full Professor, Center for Human Genetics, KULeuven
 * Director, VIB Center of Cancer Biology
 * Expert in big data, omics and computational biology
 * ISI highly cited researcher



DIETHER LAMBRECHTS

Investment Advisory Board


 * BA UC Berkeley
 * PhD UC San Diego and Salk
 * UCSF and QB3: Founder, Entrepreneurship
 * Executive and consultant: Array (PFE), Osel, Presage
 * AbbVie Ventures
 * Board roles: Ambagon, Nitrase, PACT, eFFECTOR (EFTR), Tizona (GILD), Stemson,
   ESCAPE Bio, VentureWell



KT MOORTGAT

Investment Partner


SARA MORREN

PA Managing Partner & HR Manager


 * PhD in Biomedical Sciences, University of Leuven
 * Doctoral Researcher in Alzheimer's disease, VIB
 * M.Sc. Biochemistry and Biotechnology, University of Antwerp
 * Master Thesis, MolGen department, VIB
 * Internship Master, diagnostic tests for breast cancer, Multiplicom NV Niel



DIETER PETIT

Scientific Analyst Genetic Diseases


 * Professor of Cancer Immunology and Immunotherapy at UCL Cancer Institute
 * Group Leader of the Immune Regulation and Tumour Immunotherapy Laboratory
 * CRUK Senior Cancer Research Fellow
 * Co-leading scientist CRUK Cancer Immunotherapy Accelerator
 * CSO at Achilles Therapeutics



SERGIO QUEZADA

Investment Advisory Board


 * Executive Chairman of RGenix, Inc
 * Board Member at Biogen, Navidea, Fortress Biotech, Verastem
 * Chief Medical Office/Scientific Advisor: Hummingbird Biosciences, Oncotartis,
   Lokon
 * Oncology Advisor, Everest Medicines



ERIC ROWINSKY

Investment Advisory Board


 * M. Sc. Biomedical Sciences, University of Leuven
 * PhD Biomedical Sciences – Angiogenesis and Metabolism, University of Leuven
 * Starter Fellowship Emmanuelle van der Schueren, VLK
 * PhD fellow IWT & Post-doc fellow FWO

* representing Sascon BV

SANDRA SCHOORS *

Associate Partner


 * Professor in the Department of Neurosciences at KU Leuven
 * Group leader at the VIB Center for Brain & Disease Research.
 * Head of the Laboratory of Neurobiology at VIB
 * Scientific Founder of Augustine Therapeutics



LUDO VAN DEN BOSCH

Investment Advisory Board


 * Associate Professor in the Department of Biology at the Massachusetts
   Institute of Technology
 * Associate Director of the Koch Institute for Integrative Cancer Research
 * Institute Member of the Broad Institute of Harvard and MIT
 * Instructor of Medicine at the Dana-Farber Cancer Institute and Harvard
   Medical School



MATTHEW VANDER HEIDEN

Investment Advisory Board


 * M.Sc. Biochemistry & Biotechnology Ghent University - VIB
 * Postgraduate Corporate Finance University of Leuven
 * Turnstone Communications
 * KBC Securities - Equity Research
 * KBC Securities - Associate Director Corporate Finance



LENNY VAN STEENHUYSE

Principal


 * M. Sc. Biomedical Sciences, University of Leuven
 * PhD Biomedical Sciences – Tumor Immunology, University of Leuven
 * PhD Pharmaceutical Sciences – Polymers, ULB
 * PhD fellow IWT
 * Recipient VCU RDD Peter R. Byron Graduate Student Award
 * Belgian Brain Tumor Support

* Representing KinCon BV

MATTHIAS VAN WOENSEL *

Associate Partner


EVELIEN VERDRENGH

Office Manager & Executive Assistant






DROIA LABS



Droia Labs is the scientific arm of Droia Ventures and validates novel ideas for
young drug development companies. Droia Labs provides state-of-the-art
facilities to deliver cutting edge science on groundbreaking ideas. With our
team of seasoned scientists and entrepreneurs we make our contribution to
ultimately deliver life-changing medicines to patients in need.

KRIS NYS

VP R&D – Droia Labs


 * PhD Medical Sciences, DNA damage in cancer, University of Cambridge, UK
 * Postdoctoral Fellow, novel drug targets in a rare cancer, New York University
   Langone Health, USA
 * Recipient Cancer Research UK PhD Fellowship
 * Scientific publications in e.g. JNCI, Oncotarget, Eur J Hum Genet



ELKE VAN OUDENHOVE

Director Scientific Operations – Droia Labs


AN STEENSELS

Labmanager – Droia Labs


STÉPHANIE PHILTJENS

Bioinformatician – Droia Labs


KATLEEN BREPOELS

Labtechnician – Droia Labs


KATLEEN SONCK

Senior Scientist – Droia Labs


JORIS SOUFFREAU

Labtechnician – Droia Labs




NEWS


 * 11 October, 2022
   Share
    * 
    * 
   
   MUNA THERAPEUTICS AWARDED $4.9M GRANT FROM THE MICHAEL J. FOX FOUNDATION FOR
   PARKINSON’S RESEARCH

 * 12 September, 2022
   Share
    * 
    * 
   
   VOLASTRA THERAPEUTICS NAMED ONE OF FIERCE BIOTECH’S “FIERCE 15” COMPANIES OF
   2022

 * 28 July, 2022
   Share
    * 
    * 
   
   VICINITAS THERAPEUTICS LAUNCHES WITH $65 MILLION IN SERIES A FINANCING TO
   ADVANCE PRECISION MEDICINES TO STABILIZE KEY PROTEINS TO TREAT DISEASE

More news
 * 11
   Oct
   
   MUNA THERAPEUTICS AWARDED $4.9M GRANT FROM THE MICHAEL J. FOX FOUNDATION FOR
   PARKINSON’S RESEARCH
   
   “We are very pleased to receive this significant funding from The Michael J.
   Fox Foundation to fund this promising research which has the potential to
   significantly improve the lives of people with Parkinson’s," said Rita
   Balice-Gordon, Chief Executi...
   
   Share
    * 
    * 

 * 12
   Sep
   
   VOLASTRA THERAPEUTICS NAMED ONE OF FIERCE BIOTECH’S “FIERCE 15” COMPANIES OF
   2022
   
   Vicinitas Therapeutics has exclusively licensed the DUBTAC platform from both
   UC Berkeley and Novartis and aims to become the leading company in targeted
   protein stabilization by developing next-generation disease therapies against
   an entire class of...
   
   Share
    * 
    * 

 * 28
   Jul
   
   VICINITAS THERAPEUTICS LAUNCHES WITH $65 MILLION IN SERIES A FINANCING TO
   ADVANCE PRECISION MEDICINES TO STABILIZE KEY PROTEINS TO TREAT DISEASE
   
   Vicinitas Therapeutics has exclusively licensed the DUBTAC platform from both
   UC Berkeley and Novartis and aims to become the leading company in targeted
   protein stabilization by developing next-generation disease therapies against
   an entire class of...
   
   Share
    * 
    * 


CAREERS



Droia is currently recruiting for its investment and development team. The team
scouts for new opportunities, evaluates companies and projects, manages the
investment and exit process, and works with the portfolio companies on their
progress.

Team members work closely with the portfolio companies at management or board
level, and play a hands-on role in all aspects of the drug development process.

Droia is an entrepreneurial environment, where everyone is above all committed
to making things happen.

Applicants should have relevant experience in biomedical science, drug
development and/or life science investing.

DROIA VENTURES IS CURRENTLY LOOKING FOR A


Bioinformatician
Lab Technician
Scientist


CONTACT US






EMAIL



contact@droiaventures.com


LINKEDIN



linkedin.com/company/droia


Zum Verschieben drückst du die Pfeiltasten entsprechend.





←Nach links→Nach rechts↑Nach oben↓Nach unten+Heranzoomen-HerauszoomenPos1Um 75 %
nach linksEndeUm 75 % nach rechtsBild aufUm 75 % nach obenBild abUm 75 % nach
unten














Kurzbefehle
KartendatenKartendaten © 2022
Kartendaten © 2022
200 m 

Nutzungsbedingungen
Fehler bei Google Maps melden



DROIA SA

28, Boulevard Joseph II
L-1840 Luxembourg
Luxembourg

  Tel. +352 203 01 236

Zum Verschieben drückst du die Pfeiltasten entsprechend.





←Nach links→Nach rechts↑Nach oben↓Nach unten+Heranzoomen-HerauszoomenPos1Um 75 %
nach linksEndeUm 75 % nach rechtsBild aufUm 75 % nach obenBild abUm 75 % nach
unten














Kurzbefehle
KartendatenKartendaten © 2022 Google
Kartendaten © 2022 Google
200 m 

Nutzungsbedingungen
Fehler bei Google Maps melden



DROIA VENTURES

Da Vincilaan 1
1930 Zaventem
Belgium

  Tel. +32 2 880 67 30

DROIA SA (LUX)  |  DROIA VENTURES (BE)
contact@droiaventures.com

ESG Disclosures

© DROIA — website made by design

Notifications